Details:
This is a Phase I clinical trial involving 36 healthy volunteers and will be carried out at the Ramón y Cajal University Hospital in Madrid (Spain). This study will evaluate the safety of SYL1801 at different doses, along with the pharmacokinetic profile of the product.
Lead Product(s): SYL18001
Therapeutic Area: Ophthalmology Product Name: SYL18001
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2021